A Study in Cancer Patients to Evaluate the Ability of LY2603618 to Act as an Inhibitor of CYP2D6 Using Desipramine as a Probe Substrate.

Trial Profile

A Study in Cancer Patients to Evaluate the Ability of LY2603618 to Act as an Inhibitor of CYP2D6 Using Desipramine as a Probe Substrate.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2013

At a glance

  • Drugs Rabusertib (Primary) ; Desipramine; Gemcitabine; Pemetrexed
  • Indications Major depressive disorder; Solid tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 21 Feb 2012 Planned end date changed from 1 Mar 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top